Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cells (Alliancells)
- Development stage
- Unknown
- Lead developer
- Alliancells
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) developed by Alliancells Bioscience are an allogeneic cell therapy being investigated for the treatment of rheumatoid arthritis (RA). These multipotent stem cells possess potent immunomodulatory and anti-inflammatory properties. Upon administration, UC-MSCs migrate to sites of inflammation where they suppress the overactive immune response characteristic of RA by inhibiting the proliferation of pro-inflammatory T cells (Th1 and Th17) and promoting the expansion of regulatory T cells (Tregs). They also modulate the activity of B cells, natural killer cells, and dendritic cells through the secretion of soluble factors such as indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), and transforming growth factor-beta (TGF-β). This therapy aims to restore immune homeostasis and reduce joint damage in patients, particularly those who are refractory to conventional disease-modifying antirheumatic drugs (DMARDs).
- Other names
- human umbilical cord-derived mesenchymal stem cellsAlliancells UC-MSCs
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cells (Alliancells).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (Alliancells).